GlobeNewswire: Conatus Pharmaceuticals Inc. Contains the last 10 of 164 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T05:24:36ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2020/05/18/2034905/0/en/Leading-Independent-Proxy-Advisory-Firms-Recommend-Conatus-Pharmaceuticals-Shareholders-Vote-in-Favor-of-its-Merger-with-Histogen-and-the-Required-Reverse-Stock-Split.html?f=22&fvtc=4&fvtv=19743Leading Independent Proxy Advisory Firms Recommend Conatus Pharmaceuticals Shareholders Vote in Favor of its Merger with Histogen and the Required Reverse Stock Split2020-05-18T12:00:00Z<![CDATA[SAN DIEGO, May 18, 2020 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that Institutional Shareholder Services Inc. (ISS) and Glass Lewis, two leading independent research and proxy advisory firms that provide institutional investors with voting assessment and recommendations, have recommended that Conatus stockholders vote “FOR” Conatus’ proposed merger with Histogen Inc. (“Histogen”) and “FOR” Conatus’ proposed reverse stock split, both of which are to be considered at Conatus’ upcoming special meeting of stockholders to be held on May 21, 2020.]]>https://www.globenewswire.com/news-release/2020/05/14/2033447/0/en/Histogen-Publishes-Preclinical-Data-on-its-HST-004-Spinal-Disc-Program.html?f=22&fvtc=4&fvtv=19743Histogen Publishes Preclinical Data on its HST 004 Spinal Disc Program2020-05-14T12:00:00Z<![CDATA[SAN DIEGO, May 14, 2020 (GLOBE NEWSWIRE) -- Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today the publication of data on HST 004, its patented, naturally-derived material for spinal disc repair in the Journal of Medicine and Surgical Sciences.]]>https://www.globenewswire.com/news-release/2020/05/11/2031027/0/en/Histogen-Receives-US-FDA-IND-Approval-to-Initiate-Phase-1b-2a-Trial-of-HST-001-in-Androgenic-Alopecia.html?f=22&fvtc=4&fvtv=19743Histogen Receives US FDA IND Approval to Initiate Phase 1b/2a Trial of HST 001 in Androgenic Alopecia2020-05-11T12:00:00Z<![CDATA[SAN DIEGO, May 11, 2020 (GLOBE NEWSWIRE) -- Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for HST 001, the Company’s lead therapeutic candidate for the treatment of androgenic alopecia in men.]]>https://www.globenewswire.com/news-release/2020/05/07/2029863/0/en/The-Conatus-Pharmaceuticals-Special-Meeting-of-Stockholders-Seeking-Approval-for-Proposed-Merger-with-Histogen-Inc-will-Reconvene-on-May-21-2020.html?f=22&fvtc=4&fvtv=19743The Conatus Pharmaceuticals Special Meeting of Stockholders Seeking Approval for Proposed Merger with Histogen Inc. will Reconvene on May 21, 20202020-05-07T20:05:00Z<![CDATA[SAN DIEGO, May 07, 2020 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today convened and adjourned its special meeting of stockholders in order to obtain a quorum and specific stockholder approvals required pursuant to the terms of its merger agreement with Histogen Inc.]]>https://www.globenewswire.com/news-release/2020/05/01/2026328/0/en/Conatus-Pharmaceuticals-Reports-First-Quarter-2020-Financial-Results-and-Strategic-Process-Update.html?f=22&fvtc=4&fvtv=19743Conatus Pharmaceuticals Reports First Quarter 2020 Financial Results and Strategic Process Update2020-05-01T20:05:00Z<![CDATA[SAN DIEGO, May 01, 2020 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the first quarter ended March 31, 2020 and provided an update on its strategic process.]]>https://www.globenewswire.com/news-release/2020/04/20/2018547/0/en/Histogen-Announces-Investigational-Device-Exemption-Application-for-HST-002.html?f=22&fvtc=4&fvtv=19743Histogen Announces Investigational Device Exemption Application for HST 0022020-04-20T12:00:00Z<![CDATA[SAN DIEGO, April 20, 2020 (GLOBE NEWSWIRE) -- Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today that it has submitted an Investigational Device Exemption (IDE) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of HST 002 for the treatment of facial folds and wrinkles.]]>https://www.globenewswire.com/news-release/2020/04/15/2016376/0/en/Histogen-Publishes-New-Preclinical-Data-on-its-HST-003-Orthopedic-Program.html?f=22&fvtc=4&fvtv=19743Histogen Publishes New Preclinical Data on its HST 003 Orthopedic Program2020-04-15T12:00:00Z<![CDATA[SAN DIEGO, April 15, 2020 (GLOBE NEWSWIRE) -- Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today the publication of data on its human extracellular matrix (hECM) for cartilage regeneration in the Journal of Orthopaedic and Trauma Care.]]>https://www.globenewswire.com/news-release/2020/04/06/2012066/0/en/Histogen-Announces-Investigational-New-Drug-Application-Amendment-for-HST-001.html?f=22&fvtc=4&fvtv=19743Histogen Announces Investigational New Drug Application Amendment for HST 0012020-04-06T12:00:00Z<![CDATA[SAN DIEGO, April 06, 2020 (GLOBE NEWSWIRE) -- Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today that it has submitted an Investigational New Drug (IND) amendment with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1b/2a clinical trial of its lead program, HST 001 for the treatment of androgenic alopecia in men.]]>https://www.globenewswire.com/news-release/2020/03/11/1999068/0/en/Conatus-Pharmaceuticals-Reports-2019-Financial-Results-and-Strategic-Process-Update.html?f=22&fvtc=4&fvtv=19743Conatus Pharmaceuticals Reports 2019 Financial Results and Strategic Process Update2020-03-11T20:45:00Z<![CDATA[SAN DIEGO, March 11, 2020 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the fourth quarter and full year ended December 31, 2019, and provided an update on its strategic process.]]>https://www.globenewswire.com/news-release/2020/01/28/1976385/0/en/Conatus-Pharmaceuticals-and-Histogen-Enter-into-Definitive-Merger-Agreement.html?f=22&fvtc=4&fvtv=19743Conatus Pharmaceuticals and Histogen Enter into Definitive Merger Agreement2020-01-28T21:05:00Z<![CDATA[Proposed Merger Creates Regenerative Medicine Company with Three Clinical-stage Product Candidates and Combined Company Capitalization Expected to Support Operations into 2021]]>